COMMUNIQUÉS West-GlobeNewswire
-
TimelyCare Expands Its Basic Needs Service to Help Colleges Better Support Student Retention
30/04/2026 -
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
30/04/2026 -
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
30/04/2026 -
Centre for Neuro Skills CEO David Harrington Joins Brain to Brain Podcast to Discuss the Science of Recovery, Advocacy for Brain Injury Care and Why It Is Never Too Late
30/04/2026 -
Precision Neuroscience™ Partners With UChicago Medicine Researchers to Advance Brain–Computer Interface Research
30/04/2026 -
VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery
30/04/2026 -
EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer
30/04/2026 -
TOMI Environmental Solutions Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers
30/04/2026 -
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
30/04/2026 -
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
30/04/2026 -
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
30/04/2026 -
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
30/04/2026 -
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
30/04/2026 -
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026 -
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
30/04/2026 -
Verano Announces Strong First Quarter 2026 Financial Results Highlighted by $208 Million in Revenue
30/04/2026 -
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026 -
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
30/04/2026 -
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
Pages